Market Research Report Diabetes & Obesity Drug Development PipelineReview | Page 2

for T2DM, it is likely that the T2DM pipeline will continue to grow with the rising
obesity incidence.
Scope:
 Which companies are the most active within the pipeline for diabetes and
obesity?
 Which pharmaceutical approaches are the most prominent at each stage of the
pipeline and within each indication?
 To what extent do universities and institutions play a role within this pipeline,
compared with pharmaceutical companies?
 What are the most important R&D milestones and data publications to have
occurred in this disease area?
Reasons to buy
 Understand the overall pipeline, with an at-a-glance overview of all products
in therapeutic development for each indication.
 Assess the products in development in granular detail, with an up-to-date
overview of each individual pipeline program in each indication, and a
comprehensive picture of recent updates and milestones for each.
 Analyze the companies, institutions and universities currently operating in the
pipeline, and the products being fielded by each of these.
 Understand the composition of the pipeline in terms of molecule type,
molecular target, and mechanism of action and route of administration.
Table of Contents:






List of Tables
List of Figures
Diabetes and Obesity Report Coverage
Type 1 Diabetes (Juvenile Diabetes) Overview
Type 2 Diabetes Overview
Obesity Overview